Raymond James & Associates Arrowhead Pharmaceuticals, Inc. Transaction History

Raymond James & Associates

$161 Billion
Q3 2024

A detailed history of Raymond James & Associates transactions in Arrowhead Pharmaceuticals, Inc. stock. As of the latest transaction made, Raymond James & Associates holds 10,273 shares of ARWR stock, worth $201,658. This represents 0.0% of its overall portfolio holdings.

Number of Shares

10,273

Previous 10,026 2.46%

Holding current value

$201,658

Previous $260,000 23.85%

% of portfolio

0.0%

Previous 0.0%

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 18, 2024	BUY	$19.36 - $29.54 $4,781 - $7,296	247 Added 2.46%	10,273 $198,000
Q2 2024 Jul 19, 2024	BUY	$21.87 - $28.24 $9,841 - $12,708	450 Added 4.7%	10,026 $260,000
Q1 2024 Apr 22, 2024	SELL	$27.21 - $39.48 $314,057 - $455,678	-11,542 Reduced 54.65%	9,576 $273,000
Q4 2023 Jan 16, 2024	SELL	$21.2 - $31.03 $153,170 - $224,191	-7,225 Reduced 25.49%	21,118 $646,000
Q3 2023 Oct 24, 2023	BUY	$26.2 - $36.08 $240,175 - $330,745	9,167 Added 47.8%	28,343 $761,000
Q2 2023 Jul 25, 2023	SELL	$25.16 - $41.38 $34,393 - $56,566	-1,367 Reduced 6.65%	19,176 $683,000
Q1 2023 Apr 14, 2023	BUY	$23.68 - $38.51 $49,467 - $80,447	2,089 Added 11.32%	20,543 $521,000
Q4 2022 Feb 08, 2023	BUY	$28.0 - $40.56 $125,916 - $182,398	4,497 Added 32.22%	18,454 $748,000
Q3 2022 Oct 25, 2022	SELL	$29.63 - $48.31 $7,940 - $12,947	-268 Reduced 1.88%	13,957 $461,000
Q2 2022 Aug 12, 2022	SELL	$27.79 - $50.61 $194 - $354	-7 Reduced 0.05%	14,225 $501,000
Q1 2022 May 11, 2022	SELL	$39.62 - $69.97 $8,201 - $14,483	-207 Reduced 1.43%	14,232 $655,000
Q4 2021 Feb 08, 2022	SELL	$58.09 - $82.51 $4,763 - $6,765	-82 Reduced 0.56%	14,439 $957,000
Q3 2021 Nov 02, 2021	BUY	$58.38 - $84.96 $71,106 - $103,481	1,218 Added 9.16%	14,521 $907,000
Q2 2021 Aug 11, 2021	SELL	$62.15 - $90.32 $60,223 - $87,520	-969 Reduced 6.79%	13,303 $1.1 Million
Q1 2021 May 14, 2021	SELL	$61.35 - $90.47 $132,638 - $195,596	-2,162 Reduced 13.16%	14,272 $946,000
Q4 2020 Feb 12, 2021	SELL	$43.82 - $85.37 $64,064 - $124,810	-1,462 Reduced 8.17%	16,434 $1.26 Million
Q3 2020 Nov 04, 2020	SELL	$33.21 - $51.27 $647,927 - $1 Million	-19,510 Reduced 52.16%	17,896 $771,000
Q2 2020 Jul 28, 2020	BUY	$26.12 - $43.27 $363,303 - $601,842	13,909 Added 59.19%	37,406 $1.62 Million
Q1 2020 Apr 21, 2020	BUY	$20.56 - $63.12 $127,657 - $391,912	6,209 Added 35.92%	23,497 $676,000
Q4 2019 Feb 12, 2020	BUY	$28.14 - $73.01 $241,469 - $626,498	8,581 Added 98.55%	17,288 $1.1 Million
Q3 2019 Nov 07, 2019	BUY	$26.26 - $34.86 $228,645 - $303,526	8,707 New	8,707 $245,000

Others Institutions Holding ARWR

# of Institutions

294

Shares Held

90.8M

Call Options Held

155K

Put Options Held

426K

View Full List

About ARROWHEAD PHARMACEUTICALS, INC.

Ticker ARWR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 105,849,000
Market Cap $2.08B
Description
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...

More about ARWR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Raymond James & Associates with notifications on news.

Account

Raymond James & Associates Arrowhead Pharmaceuticals, Inc. Transaction History